---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-006489"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2023-01-11T23:59:59+00:00"
generated_at: "2026-06-20T16:23:25.148311+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioMarin estimates FY2022 total revenue of $2.09B, VOXZOGO sales $169M

## Summary
- Preliminary unaudited total revenue for FY2022 estimated at $2.09 billion.
- VOXZOGO contributed approximately $169 million in revenue for FY2022.
- Revenue figures are preliminary and subject to completion of quarterly closing procedures.
- Full FY2022 results expected to be reported in February 2023.

## SEC filing metadata
- accession: 0001193125-23-006489
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2023-01-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312523006489/0001193125-23-006489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312523006489/d405652d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-006489
- JSON: https://secwatch.observer/filing/0001193125-23-006489.json
- Plain text: https://secwatch.observer/filing/0001193125-23-006489.txt

## Key facts
- Earnings Releases
  BIOMARIN PHARMACEUTICAL INC reported the year ended December 31, 2022 results: revenue approximately $2.09 billion in total revenues (unaudited).
  - Period: the year ended December 31, 2022
  - Revenue: approximately $2.09 billion in total revenues (unaudited)
  - Result: preliminary results
  source text: based on preliminary results the Company estimates that it generated approximately $2.09 billion in total revenues (unaudited) for the year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312523006489/0001193125-23-006489-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.